Can early rituximab stop vasculitis relapses? new study aims to find out
NCT ID NCT07451847
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether giving the drug rituximab early, when signs of the disease reappear in the blood, can prevent relapses in people with certain types of vasculitis (GPA and MPA). About 70 adults who have been on maintenance rituximab for at least 18 months will be randomly assigned to either receive early rituximab or standard monitoring. The goal is to see which approach better prevents disease flare-ups over two years.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANCA ASSOCIATED VASCULITIS (AAV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital Cochin
Paris, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a targeted antibody tame kidney inflammation without heavy steroids?
- New study aims to spot eye damage early in rare vasculitis patients
- Small study tests rituximab against rare vessel disease
- New mRNA injection aims to tame autoimmune diseases
- Engineered immune cells take on lupus and scleroderma in early trial
- Experimental cell infusion aims to tame childhood autoimmune diseases